Immunodeficient mouse models have been valuable for studies of human hematopoiesis, but highfidelity recapitulation of erythropoiesis in most xenograft recipients remains elusive. Recently developed immunodeficient and Kit mutant mice, however, have provided a suitable background to achieve higher-level human erythropoiesis after long-term hematopoietic engraftment. While there has been some characterization of human erythropoiesis in these models, a comprehensive analysis from various human developmental stages has not yet been reported. Here, we have utilized cell surface phenotypes, morphologic analyses, and molecular studies to fully characterize human erythropoiesis from multiple developmental stages in immunodeficient and Kit mutant mouse models following long-term hematopoietic stem and progenitor cell engraftment. We show that human erythropoiesis in such models demonstrates complete maturation and enucleation, as well as developmentally appropriate globin gene expression. These results provide a framework for future studies to utilize this model system for interrogating disorders affecting human erythropoiesis and for developing improved therapeutic approaches.
| I N T R O D U C T I O N
While mice and other animal models have contributed substantially to our understanding of erythropoiesis, many aspects of this process are poorly conserved and appear specific to humans. [1] [2] [3] [4] In addition, studies of loss-of-function mutations in animal models frequently result in much more severe phenotypes than is observed with naturally occurring genetic variation. These limitations have motivated investigations of human erythropoiesis using improved in vitro culture approaches 5, 6 and through the use of genetic studies of common and rare variation. [7] [8] [9] [10] [11] [12] [13] Until recently, no in vivo human erythropoiesis models had been developed, despite extensive and very successful research on human hematopoiesis in immunodeficient mouse models. 14, 15 Recent groundbreaking work on immunodeficient mouse strains that also harbor Kit mutations has shown that multilineage human hematopoiesis can be achieved, including robust differentiation into a variety of myeloid lineages. [16] [17] [18] [19] [20] Indeed, far better and increased myelopoiesis is observed, as compared to prior immunodeficient xenograft models. All of these xenograft recipients have been shown to possess substantial erythroid cell content in the bone marrow. Studies of these models have shown that the erythropoiesis remains within the bone marrow and very rare circulating red blood cells have been observed. 19 This work has exclusively employed cord blood-derived cells and the extent to which the observed erythropoiesis faithfully mimics the native process at various developmental stages has not been examined.
Here we utilize surface phenotypic, morphologic, and molecular analyses to demonstrate the value of this in vivo system for modeling human erythropoiesis from multiple hematopoietic developmental stages. 
| Flow cytometry and cell sorting
Flow cytometric analyses were performed as has been described 5, 7 with anti-mouse CD45 (30-F11) or anti-human CD45 (2D1), CD235a
(HIR2), CD71 (OKT9), band 3, and CD49d (9F10) antibodies on a BD Accuri C6. Importantly, all anti-human antibodies were tested against non-engrafted mouse bone marrow and showed no binding. Flow cytometric cell sorting for CD235a 1 bone marrow cells was performed using a BD FACSAria II Cell Sorter. 
| Morphological analysis

| Globin expression analysis
RNA isolation and quantitative RT-PCR for globin genes were performed as has been described previously. 21 Globin gene analysis was performed on whole cord blood (n 5 3) and whole bone marrow extracted from recipient mice engrafted with cord blood (n 5 3) or adult CD34 1 HSPCs (n 5 3). 
| Statistical analysis
An index of length 15 k-mers was prepared from release 79 of the UCSC hg38 transcriptome using the iKallisto index. 22 Raw pairedend reads were then pseudo-aligned to this reference using Kallisto quant with the bias correction flag to account for sequence bias.
Resulting counts were summed to yield transcripts per million (TPM) for each gene. Differential gene expression in bone marrow of adult CD34 1 and cord blood CD34 1 recipient mice was quantified in R using limma to fit a linear model to the calculated TPM and eBayes to derive a corrected p value for each gene. 23, 24 Expression data has been deposited in the Gene Expression Omnibus (https://www.ncbi.
nlm.nih.gov/geo/).
| R E S U L T S A N D D I S C U S S I O N
Following transplantation and regular monitoring for engraftment from peripheral blood, we harvested bone marrow and spleens from the NBSGW engrafted recipients at 14-16 weeks post-transplantation, at a time when long-term engraftment from the transplanted HSPCs has occurred ( Figure 1A) . 16, 25, 26 While the circulating pool of human CD45 1 cells was substantially lower in recipients of adults HSPCs, which is likely reflective of varying lymphoid contributions from these two developmental stages ( Figure 1B ), the bone marrow human CD45 1 contribution was similar at this time point ( Figure 1C ). 26 The variation in hematopoietic lineage contribution was not investigated further here, given that our focus was on the characterization of human erythropoiesis.
Robust erythropoiesis could be detected in the bone marrow of mice engrafted with either adult or CB HSPCs, as assessed using the marker CD235a (glycophorin A), which is expressed on proerythroblasts and subsequent stages of maturation ( Figure 1D ). 6 We also examined whether erythropoiesis was present in the spleens of any engrafted mice and detected no signs of active erythropoiesis. Consistent with recent studies of similar models, 19 we noted no circulating erythroid cells despite high levels of these cells in the bone marrow. We used alternative surface marker phenotypes to characterize these cells, including the use of band 3 and a4 integrin (CD49d) expression 6 and observed similar levels of engraftment as for CD235a alone ( from all recipients, we found no signs of dyserythropoiesis or abnormal maturation.
While these phenotypic and morphologic analyses suggest that the erythropoiesis observed is entirely normal in the human hematopoietic xenograft recipients, we wanted to examine the molecular profiles of the cells as well. We first obtained whole bone marrow RNA samples from engrafted recipients to assess the level of various human globin genes. Consistent with the known developmental expression of the globin genes, 28 we found that while g-globin was robustly expressed in CB engrafted recipients, its expression was less than 1%
of total b-like globin gene levels in recipients of adult CD34 1 cells (Figure 3) . Importantly, while g-globin was elevated in the CB engrafted recipients, the levels were lower than found in fresh cord blood samples that we assessed (Figure 3 ), which demonstrates that the cells undergo hemoglobin switching in vivo in these immunodeficient and Kit mutant mouse models. 29 These results demonstrate how this model system faithfully mimics endogenous and developmental globin gene expression to an even better extent than can be achieved in primary cell cultures, where g-globin can continue to make up 10% of total globin genes expressed in adult-derived HSPC cultures. 30 In addition, our results suggest that globin switching can be observed in such models, although further studies to examine this process at higher resolution and across numerous time points will be necessary ( Figure 3 ). As such, this system will be incredibly valuable in pre-clinical studies of Table S1 ). Global differential expression analysis across all genes confirmed the significantly higher expression of g1-(HBG1, P 5 .005), g2-(HBG2, P < 5 3 10 While the RNA-seq data obtained is from a heterogeneous population of erythroblasts, the close resemblance in overall global gene expression between developmental stages confirms the findings we obtained from our orthogonal morphologic assessments. Furthermore, erythropoietic fidelity was confirmed via observed predominance of an EPB41
isoform that preferentially excludes exon 14 while including exon 16
( Figure 4C ), consistent with previous work on the erythroid specificity of this isoform. 12, 31 In summary, we have performed a comprehensive characterization of human erythropoiesis in NBSGW human HSPC recipients. Our findings build upon elegant studies that have characterized human hematopoiesis in such models [16] [17] [18] [19] [20] and show that various developmental stages of erythropoiesis can be robustly assayed in this system. An important limitation, however, is that no circulating red blood cells can currently be isolated from these models, although small amounts of circulating cells can be obtained through transient inhibition of reticuloendothelial cells with clodronate. 19 There has been an effort to utilize human cytokines, such as erythropoietin, but this has been shown to not improve erythropoiesis in such models. 19 It is possible that further genetic manipulation may allow for higher-level human erythropoiesis than observed here, such as through the introduction of other supportive cytokines or niche modulation in the recipients. Nonetheless, the larger number and notably fuller maturation of erythroid cells present in the bone marrow of this model system (over 10 5 erythroid cells per femur) will be valuable for studies of both normal and pathological human erythropoiesis. For example, this model will be valuable to study and develop therapeutic approaches for hemoglobin disorders, 3 diseases affecting early aspects of erythropoiesis like Diamond-Blackfan anemia, 32, 33 and disorders of terminal erythropoiesis such as the congenital dyserythropoietic anemias. 34, 35 In addition, given the recent findings that lineage commitment may already take place in stem and early progenitor cells during human hematopoiesis, 26, 36 this model will have a valuable role in interrogating the full lineage output (including erythroid commitment) of various subfractions derived from such populations.
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